Senores Pharmaceuticals Limited (SENORES) announced its unaudited financial results for the quarter and half year ended 30th September 2026, showcasing robust financial and operational performance. The company reported a 25% year-on-year increase in revenue for Q2 FY27 and a 38% rise in EBITDA, marking consistent strong growth across its businesses.

Segmental Highlights

The company’s revenue for Q2 and H1 FY27 grew by 25% and 30% respectively on a year-on-year basis. Notably, the Regulated Markets segment saw a 34% increase in revenue, while the Emerging Markets segment grew by 21% in Q2 and 25% in H1 FY27. The company’s portfolio in Regulated Markets nearly doubled, expanding from 34 ANDAs as of September 2025 to 64 ANDAs as of September 2026, with 23 commercialized products.

Operational Excellence

Despite initial set-up and operating costs associated with Zoraya and Amerisyn, EBITDA for Q2 and H1 FY27 grew by 38% and 58% respectively, with margin expansion of approximately 290 bps and 530 bps on a year-on-year basis. The company’s cash from operations stood at ₹38 crores in H1 FY27, reflecting a consistent improvement in cash flow generation.

Forward-Looking Outlook

Senores Pharmaceuticals Limited remains optimistic about its future growth trajectory, on track to deliver 30-40% revenue growth and 50-60% PAT growth in FY27. The company’s robust product pipeline, expanded manufacturing capabilities, and strong commercial launch visibility underpin its positive outlook for the year and beyond.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Senores Pharmaceuticals Limited

Senores Pharmaceuticals Limited belongs to the Healthcare › Drug Manufacturers – General sector. Here’s a quick read on where the business and the stock stand today.

Senores holds in the upper half of its 52-week range, a sign the market backs the stock. The PEG of 0.33 is extremely low. Either the market misses the growth story, or there is a catch worth investigating. Revenue grows at 159.1% and profits at 139.2% CAGR. Both numbers are exceptional. The stock holds at 69% of its 52-week range with RSI at 44. In other words, neither side has a clear edge right now. Both the business and the stock move in the right direction. Revenue grows at 159.1%, profits at 139.2%, and the PEG sits at 0.33 — below its growth rate. That combination is rare. Check Fundamentals of Senores Pharmaceuticals Limited.

CORONA Remedies Limited (CORONA) has received Good Manufacturing Practice (GMP) certification from Brazil’s National Health Surveillance Agency (ANVISA) for its Bhayla manufacturing facility in Ahmedabad. This certification covers both Oral Solid Dosage (OSD) and Women’s Hormone production lines. This milestone further strengthens CORONA’s manufacturing credentials and reaffirms its commitment to maintaining high standards of quality, compliance, and operational excellence.

Reaffirming the Philosophy of ‘One World, One Quality’

While India will remain the company’s primary market, contributing over 96% of its revenue, the ANVISA GMP certification further strengthens CORONA’s manufacturing credentials. This marks CORONA’s third major GMP accreditation, building on its EU-GMP approvals for the Women’s Hormone and OSD facilities and its EAEU-GMP certification for the OSD facility. Brazil represents one of the largest pharmaceutical markets in Latin America, with an estimated market size of USD 44 billion, presenting opportunities for pharmaceutical manufacturers with strong quality systems and regulatory capabilities.

Commitment to Quality and Compliance

Together, these recognitions reflect the company’s continued focus on strengthening quality systems, maintaining regulatory compliance, and fostering a culture of continuous improvement across its manufacturing operations. Commenting on this achievement, Mr. Viral Sitwala, Executive Director, CORONA Remedies Limited, said: “Quality has always been central to the way we work at CORONA Remedies. Our philosophy of ‘One World, One Quality’ reflects our belief that the standards we follow must remain consistent and uncompromised. The ANVISA GMP certification for our Bhayla manufacturing facility is an important recognition of the systems, discipline, and collective efforts that go into maintaining these standards. While India remains our primary market and the focus of our business, such accreditations further strengthen our manufacturing credentials and reaffirm our commitment to quality and compliance. We will continue to strengthen our capabilities and uphold the quality standards that guide everything we do.”

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of CORONA Remedies Limited

CORONA Remedies Limited belongs to the Healthcare › Drug Manufacturers – General sector. Here’s a quick read on where the business and the stock stand today.

CORONA holds in the upper half of its 52-week range, a sign the market backs the stock. The PEG of 2.07 is on the high side. However, it is acceptable for a quality compounder with a strong moat. The business compounds revenue at 16.6% and profits at 29.7% CAGR. That is strong double-digit growth on both counts. Buyers show up with 2.0x the volume of sellers. Moreover, they dominated on 17 of recent sessions versus 13 for sellers — a healthy accumulation pattern. The business grows revenue at 16.6% and profits at 29.7%, with D/E of 0.14. The stock reflects that strength. Moreover, when fundamentals and price action align, the PEG of 2.07 premium is usually justified. Check Fundamentals of CORONA Remedies Limited.

Kopran Limited (KOPRAN) announced the successful completion of a GMP inspection by the European Union Medicines Authority at its Formulation manufacturing facility in Khopoli. The inspection, conducted from September 18 to September 23, 2026, concluded with no critical observations, one major observation, and some minor observations. Notably, there were no data integrity related observations. The company is currently preparing compliance responses to the EU authorities, expected to be submitted within a fortnight.

Inspection Details

The Medicine Authority European Union (EU) inspected the Khopoli facility to ensure compliance with Good Manufacturing Practices (GMP). The team evaluated various aspects of the manufacturing process, including quality control, production, and documentation. The inspection was thorough and comprehensive, covering all critical areas of the facility.

Compliance and Future Steps

Kopran Limited is in the process of addressing the minor and major observations noted during the inspection. The company is committed to maintaining the highest standards of manufacturing and will submit the required compliance responses to the EU authorities by October 2026. This proactive approach ensures that the facility continues to meet stringent regulatory requirements.

As a result, Kopran Limited reaffirms its dedication to quality and compliance, which is essential for its reputation and continued success in the pharmaceutical industry.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Kopran Limited

Kopran Limited belongs to the Healthcare › Drug Manufacturers – General sector. Here’s a quick read on where the business and the stock stand today.

Kopran gains 33.2% over three months and trades near its 52-week highs. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. 1 loss quarter(s) over five years signals earnings fragility — not chronic but worth noting. Buyers show up with 5.0x the volume of sellers. Moreover, they dominated on 18 of recent sessions versus 12 for sellers — a healthy accumulation pattern. The stock rises 33.2% in three months. Yet revenue grows at only 7.2% and the PEG stands at 99.00. Either the market prices in a turnaround that has not shown up yet, or this is momentum without substance. Check the next two earnings prints before drawing conclusions. Check Fundamentals of Kopran Limited.